Pseudoprogression of Glioblastoma after Chemo- and Radiation Therapy: Diagnosis by Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging with Ferumoxytol versus Gadoteridol and Correlation with Survival.
Radiology., Nov (2012)
A 67 year old woman on tumor necrosis factor- alpha inhibitor therapy presenting with neurological dysfunction.
Arthritis Care Res (Hoboken)., Nov (2012)
The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma.
J Neurosurg Pediatr., Oct (2012)
Immunologic privilege in the central nervous system and the blood-brain barrier.
J. Cereb. Blood Flow Metab., Oct (2012)
Ferumoxytol-enhanced MRI to Image Inflammation within Human Brain Arteriovenous Malformations: A Pilot Investigation.
Transl Stroke Res., Jul;3(Supplement 1):166-173 (2012)
Targeting Î±V-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model.
J. Neurooncol., Oct;110(1):27-36 (2012)
Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.
J. Clin. Oncol., Jul;30(19):2408-17 (2012)
Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors.
J. Neurooncol., Aug;109(1):105-14 (2012)
Cerebrospinal fluid shunting and hearing loss in patients treated for medulloblastoma.
J Neurosurg Pediatr., Apr;9(4):421-7 (2012)
Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.
AJR Am J Roentgenol., Oct;197(4):981-8 (2011)
Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol.
Radiology., Dec;261(3):796-804 (2011)
Late occurrence of drop metastasis to the spine in a case of esthesioneuroblastoma.
J Neurosurg Spine., Nov;15(5):571-5 (2011)
MRI using ferumoxytol improves the visualization of central nervous system vascular malformations.
Stroke., Jun;42(6):1581-8 (2011)
Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.
Clin. Cancer Res., Apr;17(8):2207-15 (2011)
Engaging neuroscience to advance translational research in brain barrier biology.
Nat. Rev. Neurosci., Mar;12(3):169-82 (2011)
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
Neurology., Jan;76(1):87-93 (2011)
Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol.
Neuro-oncology., Feb;13(2):251-60 (2011)
Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models.
Neuro-oncology., Jan;13(1):51-60 (2011)
Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.
Pituitary., Mar;14(1):80-91 (2011)
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
J. Neurooncol., Jun;103(2):353-60 (2011)
Dynamic-contrast-enhanced-MRI with extravasating contrast reagent: rat cerebral glioma blood volume determination.
J. Magn. Reson., Oct;206(2):190-9 (2010)
Treatment with bevacizumab plus carboplatin for recurrent malignant glioma.
Neurosurgery., Jul;67(1):87-93 (2010)
Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Int. J. Radiat. Oncol. Biol. Phys., Feb;79(2):514-23 (2011)
Critical need for international consensus on ototoxicity assessment criteria.
J. Clin. Oncol., Apr;28(10):1630-2 (2010)
Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
Neurosurgery., Jan;66(1):48-58; discussion 58 (2010)
Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines.
Neoplasia., Oct;11(10):1003-11 (2009)
Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review.
J. Cereb. Blood Flow Metab., Jan;30(1):15-35 (2010)
Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.
J. Clin. Oncol., Jul;27(21):3503-9 (2009)
FAPP2 gene downregulation increases tumor cell sensitivity to Fas-induced apoptosis.
Biochem. Biophys. Res. Commun., May;383(2):167-71 (2009)
Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models.
Neoplasia., Feb;11(2):187-95 (2009)
Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma.
Neuro-oncology., Oct;11(5):503-13 (2009)
Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model.
J. Cereb. Blood Flow Metab., Apr;29(4):853-60 (2009)
siRNA Down-regulation of the PATZ1 Gene in Human Glioma Cells Increases Their Sensitivity to Apoptotic Stimuli.
Cancer Ther., 6(B):865-876 (2008)
Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.
Neurology., Oct;71(17):1355-60 (2008)
Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?
Kidney Int., Mar;75(5):465-74 (2009)
Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model.
Neuro-oncology., Apr;11(2):142-50 (2009)
N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase III trials.
J Vasc Interv Radiol., Mar;19(3):309-18 (2008)
Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity.
Clin. Cancer Res., Jan;14(2):533-40 (2008)
Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
Cancer., Feb;112(3):581-8 (2008)
Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report.
Blood., Feb;111(3):1085-93 (2008)
Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models.
Cancer Chemother. Pharmacol., Jul;62(2):235-41 (2008)
In vivo leukocyte labeling with intravenous ferumoxides/protamine sulfate complex and in vitro characterization for cellular magnetic resonance imaging.
Am. J. Physiol., Cell Physiol., Nov;293(5):C1698-708 (2007)
Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.
Leuk. Lymphoma., Sep;48(9):1712-20 (2007)
Diagnosis and management of primary intraocular lymphoma: an update.
Clin Ophthalmol., Sep;1(3):247-58 (2007)
Chemotherapy delivery issues in central nervous system malignancy: a reality check.
J. Clin. Oncol., Jun;25(16):2295-305 (2007)
Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma.
Clin. Cancer Res., Apr;13(8):2504-11 (2007)
The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.
Neurosurgery., Apr;60(4):601-11; discussion 611-2 (2007)
Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
J. Clin. Oncol., Apr;25(10):1190-5 (2007)
Can medical schools teach high school students to be scientists?
FASEB J., Jul;21(9):1954-7 (2007)
Distinguishing primary central nervous system lymphoma from other central nervous system diseases: a neurosurgical perspective on diagnostic dilemmas and approaches.
Neurosurg Focus., 21(5):E3 (2006)
Implications of the blood-brain barrier in primary central nervous system lymphoma.
Neurosurg Focus., 21(5):E11 (2006)
Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting.
J. Neurooncol., Jan;81(1):81-91 (2007)
International study on low-grade primary central nervous system lymphoma.
Ann. Neurol., May;59(5):755-62 (2006)
Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting.
AJNR Am J Neuroradiol., Mar;27(3):715-21 (2006)
Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.
J. Neurooncol., May;77(3):279-84 (2006)
Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
J. Clin. Oncol., Dec;23(34):8588-96 (2005)
Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor.
Neurosurgery., Oct;57(4):785-96; discussion 785-96 (2005)
An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions.
AJNR Am J Neuroradiol., Oct;26(9):2290-300 (2005)
Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption.
Pediatr Blood Cancer., Aug;47(2):174-82 (2006)
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.
J. Clin. Oncol., Aug;23(22):5034-43 (2005)
Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels.
J. Pharmacol. Exp. Ther., Sep;314(3):1052-8 (2005)
Program self-evaluation: the evolution of an injury prevention foundation.
J. Neurosurg., May;102(5):847-9 (2005)
Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10.
AJNR Am J Neuroradiol., May;26(5):1084-8 (2005)
Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery.
AJNR Am J Neuroradiol., Feb;26(2):258-65 (2005)
New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting.
Clin. Cancer Res., Jan;11(2 Pt 1):421-8 (2005)
Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma.
Clin. Cancer Res., Jan;11(1):335-40 (2005)
The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway.
J. Pharmacol. Exp. Ther., Feb;312(2):424-31 (2005)
Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours.
Neuropathol. Appl. Neurobiol., Oct;30(5):456-71 (2004)
Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model.
Hear. Res., Jul;193(1-2):25-30 (2004)
Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model.
J. Pharmacol. Exp. Ther., May;309(2):594-9 (2004)
Trafficking of superparamagnetic iron oxide particles (Combidex) from brain to lymph nodes in the rat.
Neuropathol. Appl. Neurobiol., Feb;30(1):70-9 (2004)
Mechanisms of disease: the blood-brain barrier.
Neurosurgery., Jan;54(1):131-40; discussion 141-2 (2004)
BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models.
J. Neurooncol., Oct;65(1):49-62 (2003)
Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers.
Neurosurgery., Oct;43(4):879-86; discussion 886-9 (1998)
Atypical central nervous system lymphoma at the cranial base: report of four cases.
Neurosurgery., Sep;43(3):613-5; discussion 615-6 (1998)
Differential permeability of a human brain tumor xenograft in the nude rat: impact of tumor size and method of administration on optimizing delivery of biologically diverse agents.
Clin. Cancer Res., Jun;4(6):1549-55 (1998)
Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means.
Neurosurgery., May;42(5):1083-99; discussion 1099-100 (1998)